Skip to main content
STIM logo

STIM · Neuronetics, Inc.

Track STIM — free
$1.39 -0.04 (-2.80%) At close · Nov 13
Market Cap
$108.04M
Shares
77.73M
Volume · Nov 13 16.26M Avg daily vol (3M) 1.64M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.39 Open$1.21 Day$1.20–1.44 52W close$1.18–3.30 Avg vol 30d2.1M Short int6.7M · 8.6% of shares · 9.9d Short vol15% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 16, 2027 Est · unconfirmed · in 17 wks
call held May 5, 2026

Latest documents

2026
Nov 12
Current report 8-K/A Events of Nov 10
Amendment refiles legal opinion for 18,750,000-share offering

Neuronetics amended its report solely to refile a legal opinion and consent that superseded and replaced the originals. The underlying offering covered 18,750,000 common shares at $1.60 per share.

Entered into a material agreement, Other events
2 source passages
Neuronetics, Inc. (the “Company”) is filing this Amendment No. 1 to its Current Report on Form 8-K, originally filed with the Securities and Exchange Commission on November 12, 2026 (the “Original 8-K”), solely to re-file Exhibit 5.1 and Exhibit 23.1 (included in Exhibit 5.1) to the Original 8-K, which supersede and replace in their entirety Exhibits 5.1 and 23.1 to the Original 8-K. On November 10, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (“William Blair”), as representative of the underwriters named in Schedule I attached thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 18,750,000 shares (the “Firm Securities”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price to the public of $1.60 per share (the “Offering”). Open the document at this passage
Nov 12
Current report 8-K Events of Nov 10
18,750,000-share offering priced at $1.60 per share

Neuronetics, Inc. priced an offering of 18,750,000 common shares at $1.60 per share, expecting approximately $27.7 million in net proceeds. It will use part of the proceeds to repay Perceptive Credit Holdings IV, LP term loans and for general corporate purposes.

Entered into a material agreement, Other events Read from the first part of this long document
3 source passages
On November 10, 2026, Neuronetics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (“William Blair”), as representative of the underwriters named in Schedule I attached thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 18,750,000 shares (the “Firm Securities”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price to the public of $1.60 per share (the “Offering”). The Company estimates that the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $27.7 million (or $31.9 million if the Underwriters’ option to purchase the Optional Securities is exercised in full). The Company intends to use a portion of the net proceeds from the Offering to repay a portion of the outstanding term loans under the Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Perceptive Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. Open the document at this passage
Nov 10
Current report 8-K Events of Nov 5
Credit amendment requires $15,000,000 prepayment and modifies revenue covenants

Neuronetics, Inc. entered Amendment No. 6 on November 5, 2026, modifying revenue covenants, conditional on a prepayment of no less than $15,000,000. Unless conditions are satisfied or waived by November 30, 2026, the amendment automatically terminates.

Entered into a material agreement
3 source passages
On November 5, 2026, the Company entered into Amendment No. 6 to Credit Agreement and Guaranty by and between the Company, as borrower, and Perceptive, in its capacities as administrative agent for the lender parties thereto and majority lender (the “Perceptive Sixth Amendment”). The Perceptive Sixth Amendment amends the Existing Credit Agreement to, among other things, modify certain revenue covenants, subject to the satisfaction of certain conditions, including, among other things, an optional prepayment in an amount equal to no less than $15,000,000, together with all accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and the lender parties’ other costs and expenses. Notwithstanding anything to the contrary contained herein, if the conditions precedent set forth in this Section 2.01 have not been satisfied or waived by the Administrative Agent on or prior to November 30, 2026, then this Amendment shall automatically terminate and be of no further force or effect. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises, but March 2027 covenant creates going-concern doubt

Neuronetics reported third-quarter revenue of $42.0 million, up 13%, and a $1.6 million net loss, but projected March 31, 2027 trailing revenue below its covenant minimum creates substantial going-concern doubt.

Revenue $41.96M ▲ 12.5% Net loss $1.69M Diluted EPS -$0.02
Read from the MD&A section
4 source passages
Total revenue for the three months ended September 30, 2026 was $42.0 million, an increase of $4.7 million, or 13%, compared to the three months ended September 30, 2025 revenue of $37.3 million. We incurred net losses of $1.6 million and $15.8 million for the three and nine months ended September 30, 2026, respectively compared to net losses of $9.4 million and $31.9 million for three and nine months ended September 30, 2025, respectively. The Company currently projects trailing twelve-month revenue for the period ended March 31, 2027 to be below the minimum required revenue for that period as stated in the credit facility agreement. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern. Open the document at this passage
Nov 4
Current report 8-K
Revenue rises 12.5%, adjusted EBITDA turns positive

Neuronetics reported third-quarter 2026 revenue of $42.0 million, up 12.5%, and adjusted EBITDA of $1.9 million versus $(4.7) million last year. Net loss was $1.6 million, and full-year revenue guidance remained $160 million and $164 million.

Financial results, Regulation FD disclosure Read from the first part of this long document
5 source passages
Neuronetics Reports Third Quarter 2026 Financial and Operating Results Total revenue increased 12.5% year-over-year to $42.0 million Adjusted EBITDA of $1.9 million compared to $(4.7) million in the third quarter of 2025 Net loss of $1.6 million compared to a loss of $9.4 million in the third quarter of 2025 Total revenue between $160 million and $164 million, unchanged compared to prior guidance Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$159.76M
Trailing 12 months
Net income (TTM)
−$23.35M
Trailing 12 months
Revenue growth YoY
+12.5%
Year over year
Operating margin
-9.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$39.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.4%
Year over year · more shares
Price change (1Y)
-31.9%
Trailing year
Short interest
8.6%
Latest settlement · 9.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Sell Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −41%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 10%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −26%
trailing
6-month return +14%
trailing
YTD return +1%
this year
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
71 of 86 funds reported for Sep 30 · net +1.6M sh shares · +13 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.57% of shares out · ▼ -7.6% MoM · 9.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
86 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Revenue growth +31%
Y/Y
Gross margin 137%
expanding
EPS growth +57%
Y/Y
Balance sheet $37.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 120%
annualized · 1-yr
Max drawdown −58%
past year
ATR 19.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 8
Latest guidance · from the 8-K filed Aug 11, 2026
full year 2026
Total revenue Lowered $160M – $164M
May 5, 2026 $160M – $166M changed to Aug 11, 2026 $160M – $164M
prior FY $149.16M midpoint +8.6% Y/Y
Gross margin Raised 48% – 50%
May 5, 2026 47% – 49% changed to Aug 11, 2026 48% – 50%
Operating expenses Lowered $95M – $100M
May 5, 2026 $100M – $105M changed to Aug 11, 2026 $95M – $100M
Operating expenses, less SBC Non-GAAP $91M – $96M
FY 2026
Operating Expenses Non-GAAP $91M – $96M
Cash Flow from Operations and Investing $-14.5M – $-10.5M
Previous outlook earlier release · from the Earnings Call filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Cash burn · full year $15M
Prior guidance period ended · from the Earnings Call filed Dec 31, 2025
Revenue · first quarter 2026 $33M – $35M
Guided vs delivered · last 8 settled
Revenue first quarter 2026
guided $33M – $35M
$34.45M In line
Total worldwide revenue fourth quarter of 2025
guided $40M – $43M
$41.78M In line
Total worldwide revenue third quarter of 2025
guided $37M – $39M
$37.3M In line
Total worldwide revenue full year 2025
guided $149M – $155M
$149.16M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−41% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
10% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
71 of 86 funds reported for Sep 30 · net +1.6M sh shares · +13 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.57% of shares out · ▼ -7.6% MoM · 9.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
86 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 10% Range high $3
vs 200-day avg -26% vs 50-day avg -41%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP -$6.33M Six months ended June 30 —
EBITDA non-GAAP -$9.55M Six months ended June 30 —
Net cash used in operations and investing $1.4M second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
STIM
Neuronetics, Inc.
this stock
$108.04M +0.7% +30.5% — 8.6%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
86
% held
49.9%
Reported
71 of 86
Top holder
Madryn Asset Management,…
Held Float
View
Held by Funds
Fund positions
24
View
Short & Settlement
Short Interest Falling
Shares short
6.7M
Days to cover
9.9d
Change
-550.7K sh
View
Short Volume
Short vol %
15%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
5.9K
Value
$16.9K
As of
Sep 24, 2026
View
Off-Exchange
Off-exchange %
42.6%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$149.2M
Net income (FY)
$-39.0M
EPS diluted
$-0.59
View
Filings
SEC Filings
Latest
8-K/A
Filed
Nov 12, 2026
This year
25

Neuronetics amended its report solely to refile a legal opinion and consent that superseded and replaced the originals. The underlying offering covered 18,750,000 common shares at $1.60 per share.

View
Proposed Sales
Value
$10.7K
Shares
5.1K
Filed
Nov 10, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Neuronetics Announces Proposed Pu…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
STIM -35.4% -26.3% +13.9% -38.2% +0.7%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -37.9% -25.1% +13.4% -38.0% -9.9%
Key facts CIK 1227636 CUSIP 64131A105 13F (30d) 68 filings 55 filers Visit website